NCT03675724
Alleviation by Fisetin of Frailty, Inflammation, and Related Measures in Older Adults
Enrolling by Invitation
PHASE2Ages 70+InterventionalTreatmentMayo ClinicInvestigator-initiated
~40 participants
Updated 2026-05-22 on ClinicalTrials.gov
What's tested:FisetinPlacebo oral capsule
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Decrease in blood inflammation markers
Measured over Seven Days
Conditions
Where it's being run
1 sites across 1 statesMinnesota1
Study leadership
- Robert Pignolo, MD, PhD · PRINCIPAL_INVESTIGATOR · Mayo Clinic
- Sundeep Khosla, MD · PRINCIPAL_INVESTIGATOR · Mayo Clinic
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Exclusion
Unable or unwilling to give informed consent
Pregnant
Body weight \>150 kg or body mass index (BMI) \> 50
QTc\>450 msec
Total bilirubin \>2X upper limit of normal
Inability to tolerate oral medication
Abnormality in any of the screening laboratory studies (see below)
Human immunodeficiency virus infection
Known active hepatitis B or C infection
Invasive fungal or viral infection
Known hypersensitivity or allergy to fisetin
Uncontrolled pleural/pericardial effusions or ascites
New/active invasive cancer except non-melanoma skin cancers
Subjects taking medications that are sensitive to substrates or substrates with a narrow therapeutic range for CYP3A4, CYP2C8, CYP2C9, or CYP2D6 or strong inhibitors or inducers of CYP3A4 (e.g. cyclosporine, tacrolimus or sirolimus). If antifungals are absolutely necessary from an infectious disease perspective, then they will be allowed only if the levels are therapeutic.
Strong inhibitors of CYP3A4. See Appendices 1-3.
Tyrosine kinase inhibitor therapy
Known hypersensitivity or allergy to fisetin
Subjects on quinolone antibiotic therapy for treatment or for prevention of infections within 10 days.
Subjects taking H2-antagonists and unwilling to discontinue therapy for 1 week before and 2 weeks following enrollment.
Subjects taking potentially senolytic agents within the last year: Fisetin, Quercetin, Luteolin, Dasatinib, Piperlongumine, or Navitoclax
Subjects currently taking drugs that induce cellular senescence: alkylating agents, anthracyclines, platins, other chemotherapy
Subjects taking the following antimicrobial agents: Aminoglycosides, Azole antifungals (fluconazole, miconazole, voriconazole, itraconazole), Macrolides (clarithromycin,erythromycin), Antivirals (nelfinavir, indinavir, saquinavir, ritonavir, elbasvir/grazoprevir), Rifampin
Subjects taking proton pump inhibitors who are unable or unwilling to reduce or hold therapy 2 days prior to and during the 2-day Fisetin dosing
Subjects taking the following other drugs if they cannot be held for at least 2 days before and during administration of Fisetin: digoxin, lithium, all statins, repaglidine, bosentan, gemfibrozil, olmesartan, enalapril, valsartan, methotrexate, corticosteroids, , eluxadoline, eltrombopag, nitroglycerin, pioglitazone, glyburide, enzalutamide, ezetimibe, colchicine, imatinib, cyclosporine, tacolimus, sirolimus, carbamazepine, flecainide, phenytoin, phenobarbital, rifampicin, theophylline, celecoxib, desipramine, thioridazine, venlafaxine, tizanidine, atomoxetine, voriconazole, citalopram, diazepam, escitalopram, propranolol, clozapine, cyclobenzaprine, mexiletine, olanzapine, ondansetron, riluzole
In order to ensure vitamin D sufficiency, we will also exclude subjects with serum 25-hydroxyvitamin D levels of \< 20 ng/ml.
Presence of any condition that the Investigator believes would put the subject at risk or would preclude the patient from successfully completing all aspects of the trial.
What this trial measures
- Decrease in blood inflammation markersSeven Days
Percent decrease in blood inflammation markers